ACP3 and prostate carcinoma: Sipuleucel‐T was designed to activate the patient’s immune system through ex vivo exposure to the target antigen prostatic acid phosphatase (PAP), resulting in cells of the immune system being able to detect and kill prostate cancer cells by recognition of PAP on prostate cancer cells [3, 6, 7].